In vitro emergence of carbapenem resistance in extended-spectrum β-lactamase-producing Klebsiella pneumoniae clinical isolates

Abstract

This item has no abstract. Follow the links below to access the full text.

Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations

“…There are no comparative studies between the different carbapenems for the treatment of ESBL-producing Enterobacteriaceae infections. However, in the case of ESBLproducing E. coli strains exposed to carbapenems, a greater selection of strains resistant to ertapenem and meropenem, but almost none to imipenem, has been described[109].β-lactamase inhibitors are capable of inactivating ESBL, which is not the case with chromosomal-mediated AmpC β-lactamases. Several retrospective observational studies have been conducted to assess the efficacy of BLBLI compared to carbapenems for the treatment of ESBL-producing Enterobacteriaceae infections.…”